Maplight Therapeutics (NASDAQ:MPLT) CFO Vishwas Setia Sells 10,903 Shares

Key Points

• CFO Vishwas Setia sold 36,371 shares across May 4–6 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 2.89% and generating roughly $1.02 million in proceeds.
• Maplight shares recently traded at $29.04 (50‑day MA $22.60) with a $1.24 billion market cap, but the company reported a Q1 EPS miss (‑$2.47 vs. ‑$1.05) and analysts forecast continued negative EPS for the year, highlighting ongoing cash‑burn risk.
• Analyst coverage is skewed positive with an average rating of “Moderate Buy” and an average price target of $34.43 — including high targets like $45 from HC Wainwright — yet opinions are mixed (one sell) and forecasts show larger losses ahead.

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) CFO Vishwas Setia sold 10,903 shares of the company's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $28.20, for a total transaction of $307,464.60. Following the completion of the sale, the chief financial officer owned 366,820 shares in the company, valued at approximately $10,344,324. This trade represents a 2.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Wednesday, May 6th, Vishwas Setia sold 10,564 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.24, for a total value of $298,327.36.
• On Monday, May 4th, Vishwas Setia sold 14,904 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.11, for a total value of $418,951.44.

Maplight Therapeutics Price Performance

NASDAQ MPLT traded up $1.12 on Wednesday, hitting $29.04. 267,979 shares of the stock traded hands, compared to its average volume of 342,018. The company has a 50-day moving average price of $22.60. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The stock has a market capitalization of $1.24 billion and a P/E ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by ($1.42). Research analysts expect that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MPLT. TD Cowen assumed coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They set a "buy" rating on the stock. Wall Street Zen downgraded shares of Maplight Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Canaccord Genuity Group initiated coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They set a "buy" rating and a $35.00 price objective on the stock. Needham & Company LLC started coverage on Maplight Therapeutics in a research note on Wednesday, April 8th. They issued a "buy" rating and a $37.00 target price for the company. Finally, HC Wainwright assumed coverage on Maplight Therapeutics in a report on Monday. They set a "buy" rating and a $45.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $34.43.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its position in Maplight Therapeutics by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company's stock worth $802,000 after acquiring an additional 3,608 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in shares of Maplight Therapeutics during the fourth quarter valued at $49,168,000. Invesco Ltd. bought a new stake in shares of Maplight Therapeutics during the fourth quarter valued at about $228,000. Vestal Point Capital LP acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $6,763,000. Finally, Tudor Investment Corp ET AL acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $840,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.